Case 1: Dabigatran etexilate is an orally administered prodrug that is converted to its active form, dabigatran. It is formulated as a capsule containing pellets with a tartaric acid core coated in the drug. This formulation is used to generate the acidic microenvironment required for optimal dissolution and absorption of dabigatran. There is potential for loss of potency due to moisture-induced medication degradation if the product is not stored in its original bottle (which has a desiccant) or blister packaging. In one study dabigatran etexilate capsules were openly stored for a single day at 40°C/75% humidity; and these conditions produced up to a 0.7% increase in degradation of the medication over the day. As CS’s pharmacist, it is important to counsel him to not place dabigatran in his pillbox; but rather, to keep it in its original packaging to ensure maximum stroke prevention benefit. If CS is concerned about forgetting to take his dabigatran, the pharmacist might suggest a different method for CS to remind himself, such as setting an alarm through a digital watch or cell phone or writing himself a note and placing it in or near his pillbox.
Case 2: Guidelines suggest that patients with widespread plaque psoriasis (>5% of body surface area) receive treatment with systemic non-biologic or biologic therapy or phototherapy. Since PH’s response to phototherapy was inadequate, her options at this time include biologic (adalimumab, infliximab, etanercept, and ustekinumab) and non-biologic (methotrexate, cyclosporine, and acitretin) agents. PH is of childbearing age, therefore biologics may be preferred because they are category B while methotrexate and acitretin are category X and cyclosporine is category C. In addition, cyclosporine carries a risk of hypertension which could adversely affect PH, who recently began treatment for hypertension. The 3 tumor necrosis factor inhibitors (adalimumab, infliximab, and etanercept) are equally recommended by national guidelines. Ustekinumab, an anti-IL-12/23 approved after these guidelines, has shown superior efficacy in achieving PASI-75 when compared to etanercept at 12 weeks with long term-efficacy demonstrated for responders for up to 3 years. If PH decides to initiate one of these biologic therapies, she should be sure her vaccinations are up to date since live vaccines will be contraindicated. PH should also receive a PPD test prior to therapy since the biologics carry the risk of tuberculosis and disease reactivation.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs